$BSGM
BioSig Technologies, Inc.

2024 Q4 Form 10-Q Financial Statement

#000149315224045687 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $156.0K
YoY Change -85.82%
% of Gross Profit
Depreciation & Amortization $26.59K
YoY Change -71.1%
% of Gross Profit
Operating Expenses $2.950M
YoY Change -27.2%
Operating Profit -$2.950M
YoY Change -27.18%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $15.00K
YoY Change
Pretax Income -$1.914M
YoY Change -52.74%
Income Tax
% Of Pretax Income
Net Earnings -$1.914M
YoY Change -58.09%
Net Earnings / Revenue
Basic Earnings Per Share -$0.12
Diluted Earnings Per Share -$0.12
COMMON SHARES
Basic Shares Outstanding 17.23M shares 16.28M shares
Diluted Shares Outstanding 16.20M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $615.0K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $113.0K
Receivables $81.00K
Other Receivables
Total Short-Term Assets $848.0K
YoY Change -19.31%
LONG-TERM ASSETS
Property, Plant & Equipment $111.0K
YoY Change -81.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $44.00K
YoY Change -93.6%
Total Long-Term Assets $570.0K
YoY Change -72.9%
TOTAL ASSETS
Total Short-Term Assets $848.0K
Total Long-Term Assets $570.0K
Total Assets $1.418M
YoY Change -55.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.701M
YoY Change -56.51%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.701M
Total Long-Term Liabilities
Total Liabilities $1.701M
YoY Change -58.55%
SHAREHOLDERS EQUITY
Retained Earnings -$254.2M
YoY Change 6.39%
Common Stock $17.00K
YoY Change -78.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$405.0K
YoY Change
Total Liabilities & Shareholders Equity $1.418M
YoY Change -55.04%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$1.914M
YoY Change -58.09%
Depreciation, Depletion And Amortization $26.59K
YoY Change -71.1%
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-8000 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001530766
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38659
dei Entity Registrant Name
EntityRegistrantName
BIOSIG TECHNOLOGIES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4333375
dei Entity Address Address Line1
EntityAddressAddressLine1
12424 Wilshire Blvd Suite 745
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
usd
CY2023Q3 BSGM Gain Loss On Settlement And Forgiveness Of Accounts Payable
GainLossOnSettlementAndForgivenessOfAccountsPayable
usd
BSGM Gain Loss On Settlement And Forgiveness Of Accounts Payable
GainLossOnSettlementAndForgivenessOfAccountsPayable
usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
usd
dei Document Type
DocumentType
10-Q
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90025
dei City Area Code
CityAreaCode
(203)
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17234929 shares
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2024Q3 us-gaap Cash
Cash
615000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5000 usd
CY2024Q3 us-gaap Net Investment In Lease Excluding Accrued Interest After Allowance For Credit Loss Current
NetInvestmentInLeaseExcludingAccruedInterestAfterAllowanceForCreditLossCurrent
39000 usd
CY2023Q4 us-gaap Net Investment In Lease Excluding Accrued Interest After Allowance For Credit Loss Current
NetInvestmentInLeaseExcludingAccruedInterestAfterAllowanceForCreditLossCurrent
103000 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
113000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
206000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
848000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
528000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
509000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
137000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
412000 usd
CY2024Q3 us-gaap Net Investment In Lease Excluding Accrued Interest After Allowance For Credit Loss Noncurrent
NetInvestmentInLeaseExcludingAccruedInterestAfterAllowanceForCreditLossNoncurrent
4000 usd
CY2023Q4 us-gaap Net Investment In Lease Excluding Accrued Interest After Allowance For Credit Loss Noncurrent
NetInvestmentInLeaseExcludingAccruedInterestAfterAllowanceForCreditLossNoncurrent
17000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
274000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
288000 usd
CY2024Q3 us-gaap Assets
Assets
1418000 usd
CY2023Q4 us-gaap Assets
Assets
1798000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1448000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4116000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16000 usd
CY2024Q3 us-gaap Dividends Payable Current
DividendsPayableCurrent
108000 usd
CY2023Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
101000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
145000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
349000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1701000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4582000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
103000 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
103000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
1701000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
4685000 usd
CY2024Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
105000 usd
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
105000 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16617096 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16617096 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9040043 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9040043 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
17000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
9000 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
253824000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
241988000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-254246000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245015000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-405000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-3018000 usd
CY2024Q3 us-gaap Minority Interest
MinorityInterest
17000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
26000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-388000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2992000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1418000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1798000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
156000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1145000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
736000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3916000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2763000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2815000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10559000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
253000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2950000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
4052000 usd
us-gaap Operating Expenses
OperatingExpenses
11706000 usd
us-gaap Operating Expenses
OperatingExpenses
22351000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2950000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4051000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11679000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-22345000 usd
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
8000 usd
CY2024Q3 BSGM Gain Loss On Settlement And Forgiveness Of Accounts Payable
GainLossOnSettlementAndForgivenessOfAccountsPayable
1021000 usd
BSGM Gain Loss On Settlement And Forgiveness Of Accounts Payable
GainLossOnSettlementAndForgivenessOfAccountsPayable
2409000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
38000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-225000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1914000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4050000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9240000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22562000 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-1914000 usd
us-gaap Profit Loss
ProfitLoss
-9240000 usd
us-gaap Profit Loss
ProfitLoss
-22562000 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
517000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-9000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
430000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-1914000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-4567000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9231000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22992000 usd
CY2024Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
2000 usd
CY2023Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
2000 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
7000 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
7000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
157000 usd
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1940000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4569000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9395000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22999000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.33
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16200928 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16200928 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7537237 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7537237 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13002868 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13002868 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6907790 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6907790 shares
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2992000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1251000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1040000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-190000 usd
CY2024Q1 BSGM Accretion Of Deemed Preferred Stock Dividend
AccretionOfDeemedPreferredStockDividend
133000 usd
CY2024Q1 BSGM Deemed Preferred Stock Dividend
DeemedPreferredStockDividend
133000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
2000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
420000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
636000 usd
CY2024Q2 BSGM Stock Issued During Period Value Common Stock Issued In Exchange For Principal And Accrued Interest On Note Payable
StockIssuedDuringPeriodValueCommonStockIssuedInExchangeForPrincipalAndAccruedInterestOnNotePayable
509000 usd
CY2024Q2 BSGM Stock Issued During Period Value Other One
StockIssuedDuringPeriodValueOtherOne
2534000 usd
CY2024Q2 BSGM Stock Issued During Period Value As Forgiveness Of Accounts Payable
StockIssuedDuringPeriodValueAsForgivenessOfAccountsPayable
122000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4012000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
3000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11000 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2024Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
usd
CY2024Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
usd
CY2023Q2 BSGM Stock Issued During Period Value Common Stock Issued For Exercise Of Warrants Cashlessly
StockIssuedDuringPeriodValueCommonStockIssuedForExerciseOfWarrantsCashlessly
usd
us-gaap Inventory Write Down
InventoryWriteDown
usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
usd
us-gaap Gain Loss On Sale Of Accounts Receivable
GainLossOnSaleOfAccountsReceivable
usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
usd
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
BSGM Proceeds From Proceeds From Sale Of Common Stock Under A At The Market Offerings Net Of Issuance Costs
ProceedsFromProceedsFromSaleOfCommonStockUnderAAtTheMarketOfferingsNetOfIssuanceCosts
usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
BSGM Common Stock Issued In Settlement Of Accrued Severance
CommonStockIssuedInSettlementOfAccruedSeverance
usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
usd
us-gaap Stock Issued1
StockIssued1
usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
usd
CY2024Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
usd
CY2024Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2024Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
usd
us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
usd
us-gaap Sales Type Lease Interest Income Lease Receivable
SalesTypeLeaseInterestIncomeLeaseReceivable
usd
us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
usd
BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsIntrinsicValue
usd
CY2024Q3 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue
usd
CY2024Q3 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Expected To Vest Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestIntrinsicValue
usd
CY2024Q3 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableIntrinsicValue
usd
CY2024Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
dei Local Phone Number
LocalPhoneNumber
409-5444
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q4 us-gaap Cash
Cash
190000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
81000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
44000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
44000 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18167000 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
31000 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
92000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
158000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
268000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-4050000 usd
CY2024Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
24000 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-3415000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4308000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
-3911000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1517000 usd
CY2024Q3 BSGM Accretion Of Deemed Preferred Stock Dividend
AccretionOfDeemedPreferredStockDividend
24000 usd
CY2024Q3 BSGM Deemed Preferred Stock Dividend
DeemedPreferredStockDividend
24000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
2000 usd
CY2024Q3 us-gaap Profit Loss
ProfitLoss
-1914000 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-388000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
292000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1097000 usd
CY2023Q1 BSGM Stock Issued During Period Value Issued In Settlement Of Debt
StockIssuedDuringPeriodValueIssuedInSettlementOfDebt
105000 usd
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
482000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
6748000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1052000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
2000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-7382000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1910000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
4811000 usd
CY2023Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
201000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
3245000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
1567000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-69000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
3000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-11130000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
331000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
331000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
937000 usd
CY2023Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
237000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2624000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2624000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-3000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
404000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-1296000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
2000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-4050000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1055000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1055000 usd
us-gaap Profit Loss
ProfitLoss
-9240000 usd
us-gaap Profit Loss
ProfitLoss
-22562000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
158000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
268000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
275000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
216000 usd
us-gaap Inventory Write Down
InventoryWriteDown
1307000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
253000 usd
us-gaap Gain Loss On Sale Of Accounts Receivable
GainLossOnSaleOfAccountsReceivable
-2409000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7010000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6532000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
57000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5000 usd
us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
-77000 usd
us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
-75000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-5000 usd
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
16000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
49000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-93000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
625000 usd
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-4000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-7000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4953000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
724000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-307000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-231000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4284000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14371000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
182000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-182000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
500000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4209000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12617000 usd
BSGM Proceeds From Proceeds From Sale Of Common Stock Under A At The Market Offerings Net Of Issuance Costs
ProceedsFromProceedsFromSaleOfCommonStockUnderAAtTheMarketOfferingsNetOfIssuanceCosts
-3000 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
1971000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4709000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14585000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
425000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
32000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
190000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
357000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
615000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
389000 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
122000 usd
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
105000 usd
BSGM Common Stock Issued In Settlement Of Accrued Severance
CommonStockIssuedInSettlementOfAccruedSeverance
46000 usd
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
7000 usd
us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
7000 usd
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
157000 usd
us-gaap Stock Issued1
StockIssued1
509000 usd
CY2024Q1 us-gaap Auction Market Preferred Securities Stock Series Liquidation Value
AuctionMarketPreferredSecuritiesStockSeriesLiquidationValue
35000000 usd
CY2024Q3 us-gaap Cash
Cash
600000 usd
CY2024Q3 BSGM Working Capital Deficit
WorkingCapitalDeficit
900000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4300000 usd
CY2024Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10 reverse stock split
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zWlPNahwZPC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Use of Estimates</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of these consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, stock-based compensation and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022 us-gaap Payments For Rent
PaymentsForRent
4333 usd
CY2022Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P30M
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
BSGM Lessor Sales Type Lease Discount Rate
LessorSalesTypeLeaseDiscountRate
0.02 pure
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2024Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
CY2023Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zfzmbGIXLO3l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Concentrations of Credit Risk</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At September 30, 2024 and December 31, 2023, deposits in excess of FDIC limits were $<span id="xdx_90C_eus-gaap--CashUninsuredAmount_iI_pn4n6_c20240930_zsNONlGXHRBd" title="Cash, uninsured amount">0.37</span> million and <span id="xdx_90F_eus-gaap--CashUninsuredAmount_iI_dxL_c20231231_zzTclTuMmfCb" title="Cash, uninsured amount::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0997">nil</span></span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
370000 usd
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
253000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10049328 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1910118 shares
CY2024Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
4752 usd
CY2023Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
4751 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
14254 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
14354 usd
CY2024Q3 us-gaap Product Warranty Obligation Term
ProductWarrantyObligationTerm
P2Y
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1036000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1452000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
925000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
943000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
509000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
253411 usd
CY2024Q3 us-gaap Depreciation
Depreciation
26590 usd
CY2023Q3 us-gaap Depreciation
Depreciation
87338 usd
us-gaap Depreciation
Depreciation
143804 usd
us-gaap Depreciation
Depreciation
253486 usd
CY2023 BSGM Number Of Leases
NumberOfLeases
2 integer
CY2023 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
expiring through July 31, 2025
BSGM Number Of Leases
NumberOfLeases
1 integer
us-gaap Operating Lease Payments
OperatingLeasePayments
15129 usd
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
expiring in July 31, 2025
CY2024Q3 BSGM Operating Lease Right To Use Assets Gross
OperatingLeaseRightToUseAssetsGross
502000 usd
CY2023Q4 BSGM Operating Lease Right To Use Assets Gross
OperatingLeaseRightToUseAssetsGross
995000 usd
CY2024Q3 BSGM Operating Lease Right To Use Asset Accumulated Depreciation
OperatingLeaseRightToUseAssetAccumulatedDepreciation
365000 usd
CY2023Q4 BSGM Operating Lease Right To Use Asset Accumulated Depreciation
OperatingLeaseRightToUseAssetAccumulatedDepreciation
583000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
137000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
412000 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
36565 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
95964 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
203315 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
280541 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
145000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
452000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
145000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
349000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
103000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
45000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
106000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
151000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
145000 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
36000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
84000 usd
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000 usd
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1000 usd
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
4000 usd
CY2024Q3 us-gaap Lease Cost
LeaseCost
37000 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
96000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
158000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
252000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
41000 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
22000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
4000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
7000 usd
us-gaap Lease Cost
LeaseCost
203000 usd
us-gaap Lease Cost
LeaseCost
281000 usd
CY2022 us-gaap Payments For Rent
PaymentsForRent
4333 usd
CY2022Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P30M
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
BSGM Lessor Sales Type Lease Discount Rate
LessorSalesTypeLeaseDiscountRate
0.02 pure
CY2024Q3 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
4000 usd
CY2023Q4 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
120000 usd
BSGM Sales Type Lease Invoiced To Customer
SalesTypeLeaseInvoicedToCustomer
-81000 usd
CY2024Q3 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
4000 usd
CY2024Q3 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
43000 usd
CY2022Q4 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
221000 usd
BSGM Sales Type Lease Invoiced To Customer
SalesTypeLeaseInvoicedToCustomer
-81000 usd
us-gaap Sales Type Lease Interest Income Lease Receivable
SalesTypeLeaseInterestIncomeLeaseReceivable
2000 usd
CY2023Q3 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
3000 usd
CY2023Q3 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
145000 usd
CY2024Q3 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Remainder Of Fiscal Year
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear
27000 usd
CY2024Q3 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths
13000 usd
CY2024Q3 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
4000 usd
CY2024Q3 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
44000 usd
CY2024Q3 us-gaap Sales Type And Direct Financing Leases Lease Receivable Undiscounted Excess Amount
SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount
1000 usd
CY2024Q3 us-gaap Sales Type Lease Net Investment In Lease
SalesTypeLeaseNetInvestmentInLease
43000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
256000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1277000 usd
CY2024Q3 BSGM Accrued Reimbursements Current
AccruedReimbursementsCurrent
7000 usd
CY2023Q4 BSGM Accrued Reimbursements Current
AccruedReimbursementsCurrent
9000 usd
CY2024Q3 BSGM Accrued Consulting Current
AccruedConsultingCurrent
152000 usd
CY2023Q4 BSGM Accrued Consulting Current
AccruedConsultingCurrent
804000 usd
CY2024Q3 BSGM Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
474000 usd
CY2023Q4 BSGM Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
802000 usd
CY2024Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
36000 usd
CY2023Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
333000 usd
CY2024Q3 BSGM Accrued Office Expense And Other Expense
AccruedOfficeExpenseAndOtherExpense
423000 usd
CY2023Q4 BSGM Accrued Office Expense And Other Expense
AccruedOfficeExpenseAndOtherExpense
290000 usd
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
100000 usd
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
601000 usd
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1448000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4116000 usd
CY2024Q3 BSGM Gain On Settlement And Forgiveness Of Debt
GainOnSettlementAndForgivenessOfDebt
1021000 usd
BSGM Gain On Settlement And Forgiveness Of Debt
GainOnSettlementAndForgivenessOfDebt
2409000 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10 reverse stock split
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16617096 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16617096 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9040043 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9040043 shares
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
109948 shares
CY2024Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
3000000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder.
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P10Y
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2515200 shares
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P9Y10M20D
CY2024Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1312854 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
603229 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
25.67
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2400000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.45
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
488029 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
28.97
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2515200 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.96
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y10M20D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1312854 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.41
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y10M2D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice
0.34
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.3551 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0350 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
498445 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
655863 usd
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
502662 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1142185 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
477849 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M20D
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4951068 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
2748371 shares
CY2023Q4 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
7.40
CY2023 BSGM Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2
P3Y8M12D
CY2023Q4 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue
1717104000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
2202697 shares
BSGM Share Based Compensation Arrangements By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
2.28
BSGM Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Grants Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsWeightedAverageRemainingContractualTerm2
P5Y
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
4951068 shares
CY2024Q3 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
4.92
BSGM Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2
P3Y9M18D
CY2024Q3 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Expected To Vest
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVest
4559365 shares
CY2024Q3 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested And Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestWeightedAverageExercisePrice
5.23
BSGM Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Vested And Expected To Vest Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm2
P3Y8M12D
CY2024Q3 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
4559365 shares
CY2024Q3 BSGM Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice
5.23
BSGM Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Instruments Exercisable Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageRemainingContractualTerm2
P3Y8M12D
CY2024Q3 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
12500 shares
CY2024Q3 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
275000 shares
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
123173 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1275000 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
571073 usd
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair market value for a grantee who is not 10% stockholder.
CY2024Q3 BSGM Net Income Loss Of Non Controlling Interest
NetIncomeLossOfNonControllingInterest
-0 usd
CY2024Q3 BSGM Average Noncontrolling Interest Percentage Of Profitlosses
AverageNoncontrollingInterestPercentageOfProfitlosses
0.15 pure
CY2023Q3 BSGM Net Income Loss Of Non Controlling Interest
NetIncomeLossOfNonControllingInterest
1474000 usd
CY2023Q3 BSGM Average Noncontrolling Interest Percentage Of Profitlosses
AverageNoncontrollingInterestPercentageOfProfitlosses
0.35 pure
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
517000 usd
BSGM Net Income Loss Of Non Controlling Interest
NetIncomeLossOfNonControllingInterest
-17000 usd
BSGM Average Noncontrolling Interest Percentage Of Profitlosses
AverageNoncontrollingInterestPercentageOfProfitlosses
0.52 pure
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-9000 usd
BSGM Net Income Loss Of Non Controlling Interest
NetIncomeLossOfNonControllingInterest
1176000 usd
BSGM Average Noncontrolling Interest Percentage Of Profitlosses
AverageNoncontrollingInterestPercentageOfProfitlosses
0.37 pure
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
430000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
26000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-9000 usd
CY2024Q3 us-gaap Minority Interest
MinorityInterest
17000 usd
CY2024Q2 us-gaap Defined Contribution Plan Increase Decrease Cost
DefinedContributionPlanIncreaseDecreaseCost
0 usd
us-gaap Defined Contribution Plan Increase Decrease Cost
DefinedContributionPlanIncreaseDecreaseCost
-25904 usd
CY2023Q3 us-gaap Defined Contribution Plan Increase Decrease Cost
DefinedContributionPlanIncreaseDecreaseCost
56078 usd
us-gaap Defined Contribution Plan Increase Decrease Cost
DefinedContributionPlanIncreaseDecreaseCost
118815 usd
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
1849386 usd
CY2023Q4 us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
775782 usd
CY2024Q1 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
1440000 usd
CY2024Q1 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
288000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2950000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
4052000 usd
us-gaap Operating Expenses
OperatingExpenses
11706000 usd
us-gaap Operating Expenses
OperatingExpenses
22351000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2950000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4051000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11679000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-22345000 usd
CY2024Q3 us-gaap Assets
Assets
1418000 usd
CY2023Q4 us-gaap Assets
Assets
1798000 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
15000 usd

Files In Submission

Name View Source Status
0001493152-24-045687-index-headers.html Edgar Link pending
0001493152-24-045687-index.html Edgar Link pending
0001493152-24-045687.txt Edgar Link pending
0001493152-24-045687-xbrl.zip Edgar Link pending
bsgm-20240930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
bsgm-20240930_def.xml Edgar Link unprocessable
bsgm-20240930_lab.xml Edgar Link unprocessable
bsgm-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
bsgm-20240930_cal.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending